Related Experiment Videos
TA 4-SCC versus CEA sensitivity for lung cancer
F Pecchio1, M Rapellino, E Ricci
1Laboratorio Baldi e Riberi, Ospedale S. Giovanni Battista, Torino, Italia.
Tumori
|August 31, 1988
Summary
The new TA 4-SCC tumor marker shows moderate sensitivity for lung cancer detection. It is particularly notable for its presence in early-stage lung tumors, outperforming CEA in curatively operable cases.
Area of Science:
- Oncology
- Biomarkers
- Cancer Diagnostics
Background:
- Established tumor markers like Carcinoembryonic Antigen (CEA) are used in lung cancer management.
- There is a continuous need for sensitive and specific biomarkers for early lung tumor detection and monitoring.
Purpose of the Study:
- To evaluate the diagnostic sensitivity of the novel tumor marker TA 4-SCC for lung tumors.
- To compare the performance of TA 4-SCC with the established CEA marker in lung cancer patients.
Main Methods:
- Assessing the sensitivity of TA 4-SCC in a cohort of lung tumor patients.
- Comparing TA 4-SCC sensitivity across different lung cancer histologic types.
- Evaluating TA 4-SCC and CEA sensitivity in early-stage (I and II) and curatively operable lung tumors.
Main Results:
- TA 4-SCC demonstrated moderate sensitivity (30%) for lung tumors, with no significant variation across histologic subtypes.
- A notable finding was the elevated presence of TA 4-SCC in serum from patients with early-stage lung cancer (stages I and II).
- In curatively operable lung tumors, TA 4-SCC sensitivity reached 30%, significantly higher than CEA's 10% sensitivity in the same patient group.
Conclusions:
- TA 4-SCC exhibits moderate sensitivity as a lung tumor marker.
- The marker shows promise for detecting early-stage and operable lung cancers, potentially offering an advantage over CEA in these specific contexts.